16 April 2007
The London Stock Exchange is delighted to welcome Sinclair Pharma plc to the Main Market.
Sinclair Pharma is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 65 countries.
Sinclair has expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health.
The company floated on AIM in December 2003 at 115p and a market capitalisation of £61.8m. As at close of play 11 April 2007 share price was 122.5p and market cap is now £114.8m. As part of its transfer to the Main Market, Sinclair Pharma has also applied to join techMARK mediscience.
The new listing on the Main Market is expected to increase liquidity in the ordinary shares, and enhance the domestic and international profile of the Company. In recent years, Sinclair Pharma has expanded its international presence, and now has significant and expanding activities in continental Europe.